266 related articles for article (PubMed ID: 20635974)
1. Dendritic-cell vaccination for prostate cancer.
Thomas-Kaskel AK; Veelken H
Immunotherapy; 2009 Jan; 1(1):63-72. PubMed ID: 20635974
[TBL] [Abstract][Full Text] [Related]
2. Advances in specific immunotherapy for prostate cancer.
Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
[TBL] [Abstract][Full Text] [Related]
3. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy.
Hwang C; Sanda MG
Curr Opin Mol Ther; 1999 Aug; 1(4):471-9. PubMed ID: 11713762
[TBL] [Abstract][Full Text] [Related]
4. [Vaccine therapy of prostate cancer].
Doehn C; Böhmer T; Sommerauer M; Kausch I; Jocham D
Aktuelle Urol; 2005 Sep; 36(5):407-16. PubMed ID: 16163603
[TBL] [Abstract][Full Text] [Related]
5. Cancer immunotherapy by fusions of dendritic cells and tumor cells.
Koido S; Hara E; Homma S; Ohkusa T; Gong J; Tajiri H
Immunotherapy; 2009 Jan; 1(1):49-62. PubMed ID: 20635973
[TBL] [Abstract][Full Text] [Related]
6. The immunotherapy of prostate and bladder cancer.
Totterman TH; Loskog A; Essand M
BJU Int; 2005 Oct; 96(5):728-35. PubMed ID: 16144528
[TBL] [Abstract][Full Text] [Related]
7. DC therapy for prostate cancer.
Swindle PW; Tepes S; Clements J
Cytotherapy; 2004; 6(2):164-71. PubMed ID: 15203993
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy for metastatic colorectal cancer: present status and new options.
Ellebaek E; Andersen MH; Svane IM; Straten PT
Scand J Gastroenterol; 2012 Mar; 47(3):315-24. PubMed ID: 22214467
[TBL] [Abstract][Full Text] [Related]
9. Dendritic cell-based immunotherapy for prostate cancer.
Jähnisch H; Füssel S; Kiessling A; Wehner R; Zastrow S; Bachmann M; Rieber EP; Wirth MP; Schmitz M
Clin Dev Immunol; 2010; 2010():517493. PubMed ID: 21076523
[TBL] [Abstract][Full Text] [Related]
10. Dendritic cell vaccines for the treatment of prostate cancer.
Lehrfeld TJ; Lee DI
Urol Oncol; 2008; 26(6):576-80. PubMed ID: 18996314
[TBL] [Abstract][Full Text] [Related]
11. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
12. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer.
Simons JW; Mikhak B; Chang JF; DeMarzo AM; Carducci MA; Lim M; Weber CE; Baccala AA; Goemann MA; Clift SM; Ando DG; Levitsky HI; Cohen LK; Sanda MG; Mulligan RC; Partin AW; Carter HB; Piantadosi S; Marshall FF; Nelson WG
Cancer Res; 1999 Oct; 59(20):5160-8. PubMed ID: 10537292
[TBL] [Abstract][Full Text] [Related]
13. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer.
Kim S; Lee JB; Lee GK; Chang J
Prostate; 2009 Jun; 69(9):938-48. PubMed ID: 19267351
[TBL] [Abstract][Full Text] [Related]
14. Development of dendritic-cell based prostate cancer vaccine.
Tjoa BA; Murphy GP
Immunol Lett; 2000 Sep; 74(1):87-93. PubMed ID: 10996633
[TBL] [Abstract][Full Text] [Related]
15. Dendritic cells in cancer immunotherapy.
Schuler G
Eur J Immunol; 2010 Aug; 40(8):2123-30. PubMed ID: 20853498
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy with dendritic cells for prostate cancer.
Thomas-Kaskel AK; Waller CF; Schultze-Seemann W; Veelken H
Int J Cancer; 2007 Aug; 121(3):467-73. PubMed ID: 17514654
[TBL] [Abstract][Full Text] [Related]
17. Tumor specific cytotoxicity and telomerase down-regulation in prostate cancer by autologous dendritic cells loaded with whole tumor cell antigens.
Turkeri L; Onol FF; Ozyurek M
Urol Oncol; 2010; 28(3):290-5. PubMed ID: 19362861
[TBL] [Abstract][Full Text] [Related]
18. Therapeutics targeting tumor immune escape: towards the development of new generation anticancer vaccines.
Mocellin S; Nitti D
Med Res Rev; 2008 May; 28(3):413-44. PubMed ID: 17694549
[TBL] [Abstract][Full Text] [Related]
19. Dendritic cells for specific cancer immunotherapy.
Meidenbauer N; Andreesen R; Mackensen A
Biol Chem; 2001 Apr; 382(4):507-20. PubMed ID: 11405216
[TBL] [Abstract][Full Text] [Related]
20. Dendritic cells: tools and targets for antitumor vaccination.
den Brok MH; Nierkens S; Figdor CG; Ruers TJ; Adema GJ
Expert Rev Vaccines; 2005 Oct; 4(5):699-710. PubMed ID: 16221071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
